Clinical trials: MDS-EB-1

Leukemia (Both ALL and AML), MDS-EB-1

Ikervis for DED Due to GVHD Post Allo-HSCT

• Unknown status
• Age: 13 to 95 years
• Phase 4

Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Trial name

Ikervis (NCT04636918)

Testing

Cyclosporine Ophthalmic

Where

Singapore

Volunteers

40 people

Sponsor

Singapore Eye Research Institute